IRIS
GOZZO, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.194
AS - Asia 1.734
EU - Europa 1.294
AF - Africa 208
SA - Sud America 191
Continente sconosciuto - Info sul continente non disponibili 121
OC - Oceania 6
Totale 5.748
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.126
SG - Singapore 758
CN - Cina 591
RU - Federazione Russa 531
IT - Italia 315
BR - Brasile 168
KR - Corea 166
IE - Irlanda 165
VN - Vietnam 99
CI - Costa d'Avorio 79
FR - Francia 58
CA - Canada 39
SN - Senegal 39
NG - Nigeria 37
IN - India 35
NL - Olanda 35
GB - Regno Unito 31
FI - Finlandia 30
SE - Svezia 28
BJ - Benin 19
DE - Germania 18
PL - Polonia 18
BD - Bangladesh 17
ZA - Sudafrica 17
ES - Italia 16
JP - Giappone 15
MX - Messico 14
UA - Ucraina 13
BE - Belgio 11
AR - Argentina 8
AU - Australia 6
HK - Hong Kong 6
TR - Turchia 6
CR - Costa Rica 5
IQ - Iraq 5
KE - Kenya 5
AL - Albania 4
AT - Austria 4
EG - Egitto 4
PK - Pakistan 4
VE - Venezuela 4
BS - Bahamas 3
CY - Cipro 3
DZ - Algeria 3
GR - Grecia 3
IL - Israele 3
JM - Giamaica 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
CL - Cile 2
CO - Colombia 2
CZ - Repubblica Ceca 2
EC - Ecuador 2
ID - Indonesia 2
KZ - Kazakistan 2
LV - Lettonia 2
MA - Marocco 2
NO - Norvegia 2
OM - Oman 2
PH - Filippine 2
PR - Porto Rico 2
PT - Portogallo 2
RO - Romania 2
SA - Arabia Saudita 2
UY - Uruguay 2
UZ - Uzbekistan 2
AO - Angola 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CH - Svizzera 1
DK - Danimarca 1
GM - Gambi 1
HN - Honduras 1
IR - Iran 1
IS - Islanda 1
LB - Libano 1
LT - Lituania 1
MN - Mongolia 1
MW - Malawi 1
NP - Nepal 1
PE - Perù 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TJ - Tagikistan 1
Totale 5.627
Salva come PNG Salva come JPEG
Città #
Singapore 447
Santa Clara 392
Dallas 351
Hefei 311
Moscow 230
San Jose 214
Ashburn 189
Seoul 166
Dublin 164
Chicago 87
Boardman 81
Abidjan 79
Chandler 64
Los Angeles 59
Beijing 58
Lauterbourg 53
Council Bluffs 44
Ho Chi Minh City 41
Civitanova Marche 39
Dakar 39
New York 38
Catania 34
Rome 31
Amsterdam 27
Hanoi 21
Washington 21
Cotonou 19
Stockholm 19
Lagos 18
Warsaw 18
Abuja 17
São Paulo 17
Lappeenranta 15
Milan 15
Montreal 14
Orem 14
Palermo 14
Buffalo 13
Tokyo 13
Brussels 11
Johannesburg 11
Phoenix 11
Pune 11
Atlanta 10
Boston 10
Chennai 10
Brooklyn 9
Campobasso 9
Cambridge 8
Helsinki 8
Manchester 8
Seattle 8
Jacksonville 7
Lawrence 7
Rio de Janeiro 7
Andover 6
Denver 6
Hong Kong 6
London 6
Munich 6
Poplar 6
Des Moines 5
Houston 5
Messina 5
San Giovanni la Punta 5
Toronto 5
Acalanes Ridge 4
Assago 4
Assoro 4
Augusta 4
Belo Horizonte 4
Bologna 4
Charlotte 4
City of London 4
Da Nang 4
Dong Ket 4
Florence 4
Gela 4
Las Vegas 4
Melbourne 4
Miami 4
Milwaukee 4
Piscataway 4
Reggio Calabria 4
San Francisco 4
San José 4
Secaucus 4
Trento 4
Turku 4
Anápolis 3
Cairo 3
Castelraimondo 3
Columbus 3
Espoo 3
Frankfurt am Main 3
Guarulhos 3
Kingston 3
Kirkuk 3
Lamezia Terme 3
Mexico City 3
Totale 3.817
Salva come PNG Salva come JPEG
Nome #
The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-ß1-42 oligomers in mice 166
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 166
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 159
Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure 152
Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study 149
Accesso ai medicinali innovativi per indicazioni neurologiche in Europa: allineamento delle valutazioni di Health Technology Assessment tra i Paesi Europei 145
Off-label use of drugs and adverse drug reactions in pediatric units: A prospective, multicenter study 145
Fluoxetine Protects Retinal Ischemic Damage in Mice 143
Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries 140
4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation 126
Flavan-3-ols and Vascular Health: Clinical Evidence and Mechanisms of Action 125
Editorial: Innovation in ocular pharmacology 123
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 121
Linking the Price of Cancer Drug Treatments to Their Clinical Value 120
Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network 115
EMA: l’ente che vigila sui medicinali che circolano nella Comunità Europea 114
Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough? 114
The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis 112
Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries 111
Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies 109
Fertility Preservation in Female Pediatric Patients With Cancer: A Clinical and Regulatory Issue 108
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease 107
Response to Letter to the Editor by Dr. Garattini 106
Bioequivalence, Drugs with Narrow Therapeutic Index and The Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution 105
New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review 102
Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval? 99
AIFA: l’ente che autorizza un nuovo farmaco, una nuova formulazione o una nuova indicazione in Italia 97
Sviluppo ed uso dei farmaci: dal laboratorio alla clinica. 96
Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap 96
COVID-19 Disease and Vitamin D: A Mini-Review 96
Beyond the budget silo approach: estimating health system sustainability for future dementia drugs 92
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA) 88
Attitude survey of spontaneous adverse drug-reaction reporting by general practitioners in Sicily 88
Resveratrol and vascular health: evidence from clinical studies and mechanisms of actions related to its metabolites produced by gut microbiota 87
Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries 87
Editorial: Innovative treatments for neuro-psychiatric diseases 86
OFF-LABEL USE OF MEDICINES: A CLINICAL AND REGULATORY OPPORTUNITYTHE. 40TH CONGRESS OF THE ITALIAN PHARMACOLOGICAL SOCIETY (SIF) 82
Isoflavones Effects on Vascular and Endothelial Outcomes: How Is the Gut Microbiota Involved? 81
Anemia Mediterranea o talassemia: c’è qualcosa per evitare le trasfusioni? 79
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA) 77
Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence 74
Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation 72
La sclerosi multipla: una malattia invalidante con nuove possibilità di cura 70
Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei farmaci in Italia. Rapporto Nazionale Anno 2019. Roma: Agenzia Italiana del Farmaco, 2020. 69
Scheda informativa Tocilizumab per uso endovenoso nel trattamento di pazienti gravi con COVID-19 69
Periodontal Disease and Pregnancy: Correlation with Underweight Birth 69
Obesità e farmaci: quando servono e quali usare 66
The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience 65
Starting Dose Of Non-Vitamin K Antagonist Oral Anticoagulation Agents In Patients With Atrial Fibrillation: Data From Italian Monitoring Registries 65
The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries 63
Towards a European harmonization of health technology assessment recommendations executive paper of European regulatory conference focused on the EU commission proposal to harmonize HTA 62
The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review 62
Più che una speranza, oggi è una certezza la possibilità di ridurre la gravità dell’atrofia muscolare spinale 60
Prevenzione e terapia dell’osteoporosi: quali farmaci sono utili e cosa c’è di nuovo 58
SARS-Cov-2 Damage on the Nervous System and Mental Health 58
Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei farmaci in Italia. Rapporto Nazionale Anno 2018. Roma: Agenzia Italiana del Farmaco, 2019 58
Quali farmaci usare per l’età pediatrica? 57
Asma: vecchi e nuovi farmaci e attenzione al CoViD-19 53
Phase II, noncomparative, open label, multicenter, study of osimertinib, in patients with locally advanced or metastatic EGFR mutated, T790M undetectable or unknown non-small cell lung cancer (Stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study) 53
Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database 31
Totale 5.748
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.345
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.345
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202274 0 6 3 1 8 5 6 1 10 10 5 19
2022/2023500 8 11 4 10 80 99 31 102 118 1 24 12
2023/2024448 18 58 35 42 26 97 21 39 3 13 62 34
2024/20251.404 19 161 62 64 312 162 71 40 91 110 135 177
2025/20263.212 256 396 409 212 461 647 315 48 153 152 129 34
2026/202774 39 35 0 0 0 0 0 0 0 0 0 0
Totale 5.748